RYTM:NSD-Rhythm Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 38.92

Change

-0.43 (-1.09)%

Market Cap

USD 2.30B

Volume

1.19M

Analyst Target

USD 32.88
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 109.10B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 107.30B
MRNA Moderna Inc

N/A

USD 44.96B
ARGX argenx NV ADR

N/A

USD 22.32B
BNTX BioNTech SE

N/A

USD 21.84B
GMAB Genmab AS

N/A

USD 19.15B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 18.90B
BGNE BeiGene Ltd

N/A

USD 18.28B
RPRX Royalty Pharma Plc

N/A

USD 16.78B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.29B

ETFs Containing RYTM

IWC iShares Micro-Cap ETF 0.00 % 0.60 %

N/A

USD 0.87B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.34% 40% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.34% 40% F 29% F
Trailing 12 Months  
Capital Gain 123.29% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 123.29% 92% A 95% A
Trailing 5 Years  
Capital Gain 49.00% 82% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.00% 81% B- 72% C
Average Annual (5 Year Horizon)  
Capital Gain 43.95% 85% B 89% A-
Dividend Return 43.95% 85% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 107.23% 24% F 14% F
Risk Adjusted Return 40.99% 89% A- 74% C
Market Capitalization 2.30B 91% A- 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector